Occurence of urinary tract infections in type 2 diabetes mellitus patients taking Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitors to regulate their blood sugar levels

Mahnoor Ashfaq; Sadia Shafique; Zenab Niazi; Syed Yasir Shah; Siraj Memon; Kashifa Qureshi; Faizan Banaras

doi:10.53730/ijhs.v7nS1.14444

Authors

Mahnoor Ashfaq Postgraduate Resident Internal Medicine, Ayub Teaching Hospital, Abbottabad Pakistan
Sadia Shafique House Officer Nephrology department, Khyber Teaching Hospital, Peshawar Pakistan
Zenab Niazi Postgraduate Resident Internal Medicine Pak Emirates Military Hospital (PEMH), Rawalpindi Pakistan
Syed Yasir Shah Postgraduate Resident Medicine & Allied, Khyber Teaching Hospital, Peshawar Pakistan
Siraj Memon Medical Officer, Department of Medicine, ABM Hospital, Hyderabad Pakistan
Kashifa Qureshi Medical Officer Department of Medicine, ABM Hospital, Hyderabad Pakistan
Faizan Banaras Postgraduate Resident Nephrology, Khyber Teaching Hospital, Peshawar Pakistan

Keywords:

Urinary tract infections, type 2 diabetes mellitus, sodium glucose co-transporter-2 (SGLT2) inhibitors

Abstract

Background and Aim: The occurrence of urinary tract infection (UTI) in type 2 diabetes (T2DM) administered with sodium glucose co-transporter-2 (SGLT2) inhibitors are still debatable. The present study aimed to assess the occurrence of UTI in T2DM patients taking SGLT-2 inhibitors to regulate their blood sugar levels. Patients and Methods: This cross-sectional study was carried out on 369 T2DM patients investigated in the Nephrology division of Khyber Teaching Hospital, Peshawar from January 2022 to December 2022. Dapagliflozin and empagliflozin were SGLT-2 inhibitors drugs given to each individual. Patient’s detailed history and genitourinary infections were noted from medical records. Pain during micturition, micturition urgency, redness, abdominal pain, vomiting, and frequency of micturition, fever, soreness, and diarrhea were recorded using questionnaire based proforma. Results: Of the total 369 patients, the frequency of patients administered with dapagliflozin and empagliflozin was 178 (48.2%) and 191 (51.8%) respectively. Among 178 patients, there were 112 (62.9%) male and 66 (37.1%) females. Among 191 patients, there were 136 (71.2%) male and 55 (28.8%) females. The occurrence of UTIs in patients using dapagliflozin and empagliflozin was 18 (10.1%) and 28 (14.7%) respectively.

Downloads

Download data is not yet available.

References

Suryasa IW, Rodríguez-Gámez M, Koldoris T. Health and treatment of diabetes mellitus. International Journal of Health Sciences. 2021;5(1).

Hussain A, Ali I. Diabetes mellitus in Pakistan: A major public health concern. Archives of Pharmacy Practice. 2016 Jan 1; 7(1):30-3.

Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nature Reviews Endocrinology. 2012 Aug; 8(8):495-502.

Fala L. Jardiance (empagliflozin), an SGLT2 inhibitor, receives FDA approval for the treatment of patients with type 2 diabetes. American health & drug benefits. 2015 Mar; 8(Spec Feature):92.

Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018 Oct;61: 2108-17.

Khan S, Hashmi MS, Rana MA, Zafar GM, Asif S, Farooq MT, Zahoor S, Hashmi M, Asif Sr S. Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin. Cureus. 2022 Jan 29;14(1).

Khan MU, Adnan SM, Baloch AA. Frequency of urinary tract infection in type 2 DM attending at Dow University Hospital Karachi, Pakistan. Rawal Medical Journal. 2020 Oct; 45(4):783-.

Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology. 2020 Dec; 17(12):761-72.

Evans M, Hicks D, Patel D, Patel V, McEwan P, Dashora U. Optimising the benefits of SGLT2 inhibitors for type 1 diabetes. Diabetes Therapy. 2020 Jan; 11:37-52.

Wojcik C, Warden BA. Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors. Current cardiology reports. 2019 Oct; 21:1-4.

Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Scientific reports. 2017 Jun 6; 7(1):2824.

Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Current drug safety. 2018 Jul 1; 13(2):84-91.

Borovac JA, Kurir T, Mustapic I, Kumric M, Bozic J, Glavas D, D’Amario D. SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints. Kardiologia Polska (Polish Heart Journal). 2022; 80(2):198-201.

Arakaki, R.F. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad. Med. 2016, 128, 409–417.

Figueiredo, I.R.; Rose, S.C.P.; Freire, N.B.; Patrocínio, M.S.; Pierdoná, N.; Bittencourt, R.J. Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: A systematic review. Rev. Assoc. Med. Bras. 2019, 65, 246–252.

Min, S.H.; Yoon, J.H.; Moon, S.J.; Hahn, S.; Cho, Y.M. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: A systematic review with meta-analysis. Sci. Rep. 2018, 8, 4466.

Johnston R, Uthman O, Cummins E, et al.: Corrigendum: canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2018, 21:219-20. 10.3310/hta21020-c201802.

Liu, J.; Li, L.; Li, S.; Jia, P.; Deng, K.; Chen, W.; Sun, X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci. Rep. 2017, 7, 2824.

Puckrin, R.; Saltiel, M.P.; Reynier, P.; Azoulay, L.; Yu, O.H.Y.; Filion, K.B. SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018, 55, 503–514.

Donnan, J.R.; Grandy, C.A.; Chibrikov, E.; Marra, C.A.; Aubrey-Bassler, K.; Johnston, K.; Swab, M.; Hache, J.; Curnew, D.; Nguyen, H.; et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: A systematic review and meta-analysis. BMJ Open 2019, 9, e022577.

Gadzhanova, S.; Pratt, N.; Roughead, E. Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program. Diabetes Res. Clin. Pract. 2017, 130, 180–185.

Rosenstock, J.; Seman, L.J.; Jelaska, A.; Hantel, S.; Pinnetti, S.; Hach, T.; Woerle, H.J. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes. Metab 2013, 15, 1154–1160.

Singh M, Sharma R, Kumar A. Safety of SGLT2 inhibitors in patients with diabetes mellitus. Current Drug Safety. 2019 Jul 1; 14(2):87-93.

Zheng Y, Ley SH, Hu FB: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018, 14:88-98. 10.1038/nrendo.2017.151

Chamberlain JJ, Herman WH, Leal S, Rhinehart AS, Shubrook JH, Skolnik N, Kalyani RR: Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. 2017, 166:572-8. 10.7326/M16-2937.

Rauf HA, Khan FA, Kumari K, Khan I, Ali K. Incidence and risk factors for genitourinary infection in individuals with type 2 diabetes using SGLT2 inhibitors: A retrospective study

Hsia DS, Grove O, Cefalu WT: An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017, 24:73-9. 10.1097/MED.0000000000000311.

Heald AH, Fryer AA, Anderson SG, et al.: Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: impact on glycaemic control at a general practice level in England. Diabetes Obes Metab. 2018, 20:1659-69. 10.1111/dom.13281